Hydroxychloroquine free base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317510

CAS#: 118-42-3 (free base)

Description: Hydroxychloroquine is an autophagy inhibitor. It acts by inducing apoptosis of renal cancer cells in vitro and inhibiting TLR9. Hydroxychloroquine (HCQ) is a medication used to prevent and treat malaria in areas where malaria remains sensitive to chloroquine. Other uses include treatment of rheumatoid arthritis, lupus, and porphyria cutanea tarda. It is taken by mouth. It is also being studied as an experimental treatment for coronavirus disease 2019 (COVID-19).

Chemical Structure

Hydroxychloroquine free base
CAS# 118-42-3 (free base)

Theoretical Analysis

MedKoo Cat#: 317510
Name: Hydroxychloroquine free base
CAS#: 118-42-3 (free base)
Chemical Formula: C18H26ClN3O
Exact Mass: 335.1764
Molecular Weight: 335.876
Elemental Analysis: C, 64.37; H, 7.80; Cl, 10.55; N, 12.51; O, 4.76

Price and Availability

Size Price Availability Quantity
10.0mg USD 295.0 2 Weeks
50.0mg USD 750.0 2 Weeks
5.0g USD 2950.0 4-6 weeks
10.0g USD 3850.0 4-6 weeks
20.0g USD 4850.0 4-6 weeks
50.0g USD 6450.0 4-6 weeks
Bulk inquiry

Related CAS #: 118-42-3 (free base)   747-36-4 (sulfate)   6168-85-0 (phosphate)   137433-23-9 (R-free)   137433-24-0 (S-free)    

Synonym: Hydrochloroquine; Ercoquin; Plaquinol; Toremonil; Oxychlorochin; Oxychloroquine; Plaquenil; WIN 1258; Z0188;

IUPAC/Chemical Name: 2-((4-((7-chloroquinolin-4-yl)amino)pentyl)(ethyl)amino)ethan-1-ol


InChi Code: InChI=1S/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21)


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 335.876 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Xie W, Wang Y, Zhang Z. Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality? Ann Rheum Dis. 2020 Apr 21:annrheumdis-2020-217556. doi: 10.1136/annrheumdis-2020-217556. Epub ahead of print. PMID: 32317316.

2: Moiseev S, Avdeev S, Brovko M, Novikov P, Fomin V. Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)? Ann Rheum Dis. 2020 Apr 21:annrheumdis-2020-217570. doi: 10.1136/annrheumdis-2020-217570. Epub ahead of print. PMID: 32317315.

3: Aduriz-Lorenzo PM, Aduriz-Llaneza P, Araiz-Iribarren J, Khamashta MA. Current opinion on hydroxychloroquine-related retinal toxicity screening: where do we stand now? Lupus. 2020 Apr 21:961203320919499. doi: 10.1177/0961203320919499. Epub ahead of print. PMID: 32316844.

4: Sun Y, Zhang J, Li X, Sun E. [Hydroxychloroquine alleviates 5-fluorouracil- induced enteritis in mice and its mechanism]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2020 Jan;36(1):1-8. Chinese. PMID: 32314717.

5: Falcão MB, Pamplona de Góes Cavalcanti L, Filgueiras Filho NM, Antunes de Brito CA. Case Report: Hepatotoxicity Associated with the Use of Hydroxychloroquine in a Patient with Novel Coronavirus Disease (COVID-19). Am J Trop Med Hyg. 2020 Apr 17. doi: 10.4269/ajtmh.20-0276. Epub ahead of print. PMID: 32314698.

6: Lazaros G, Antonopoulos AS, Antonatou K, Skendros P, Ritis K, Hadziyannis E, Lazarou E, Leontsinis I, Simantiris S, Vlachopoulos C, Tousoulis D, Vassilopoulos D. Hydroxychloroquine for colchicine-resistant glucocorticoid- dependent idiopathic recurrent pericarditis: A pilot observational prospective study. Int J Cardiol. 2020 Mar 30:S0167-5273(20)30011-5. doi: 10.1016/j.ijcard.2020.03.069. Epub ahead of print. PMID: 32312616.

7: Rathi S, Ish P, Kalantri A, Kalantri S. Hydroxychloroquine prophylaxis for COVID-19 contacts in India. Lancet Infect Dis. 2020 Apr 17:S1473-3099(20)30313-3. doi: 10.1016/S1473-3099(20)30313-3. Epub ahead of print. PMID: 32311324; PMCID: PMC7164849.

8: Principi N, Esposito S. Chloroquine or hydroxychloroquine for prophylaxis of COVID-19. Lancet Infect Dis. 2020 Apr 17:S1473-3099(20)30296-6. doi: 10.1016/S1473-3099(20)30296-6. Epub ahead of print. PMID: 32311322; PMCID: PMC7164862.

9: Taccone FS, Gorham J, Vincent JL. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. Lancet Respir Med. 2020 Apr 15:S2213-2600(20)30172-7. doi: 10.1016/S2213-2600(20)30172-7. Epub ahead of print. PMID: 32304640; PMCID: PMC7159849.

10: Zhu X, Sun J. A case of facial atrophic sarcoidosis in an adolescent, successfully treated by the combination of prednisone and hydroxychloroquine. An Bras Dermatol. 2020 Mar 19:S0365-0596(20)30076-3. doi: 10.1016/j.abd.2019.08.028. Epub ahead of print. PMID: 32299736.

11: Sarma P, Kaur H, Kumar H, Mahendru D, Avti P, Bhattacharyya A, Prajapat M, Shekhar N, Kumar S, Singh R, Singh A, Dhibar DP, Prakash A, Medhi B. Virological and Clinical Cure in Covid-19 Patients Treated with Hydroxychloroquine: A Systematic Review and Meta-Analysis. J Med Virol. 2020 Apr 16. doi: 10.1002/jmv.25898. Epub ahead of print. PMID: 32297988.

12: Costanzo M, De Giglio MAR, Roviello GN. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus. Curr Med Chem. 2020 Apr 16. doi: 10.2174/0929867327666200416131117. Epub ahead of print. PMID: 32297571.

13: Sinha N, Balayla G. Hydroxychloroquine and covid-19. Postgrad Med J. 2020 Apr 15:postgradmedj-2020-137785. doi: 10.1136/postgradmedj-2020-137785. Epub ahead of print. PMID: 32295814.

14: Heldwein FL, Calado A. Does hydroxychloroquine prevent the transmission of covid-19? Ann Rheum Dis. 2020 Apr 15:annrheumdis-2020-217501. doi: 10.1136/annrheumdis-2020-217501. Epub ahead of print. PMID: 32295788.

15: Joob B, Wiwanitkit V. SLE, hydroxychloroquine and no SLE patients with covid-19: a comment. Ann Rheum Dis. 2020 Apr 15:annrheumdis-2020-217506. doi: 10.1136/annrheumdis-2020-217506. Epub ahead of print. PMID: 32295787.

16: Graef ER, Liew JW, Putman MS, Simard JF, Sirotich E, Berenbaum F, Duarte- García A, Grainger R, Harrison C, Konig MF, Korsten P, Proulx L, Richards DP, Robinson PC, Sattui SE, Ugarte-Gil MF, Young KJ, Kim AH, Sparks JA; COVID-19 Global Rheumatology Alliance. Festina lente: hydroxychloroquine, covid-19 and the role of the rheumatologist. Ann Rheum Dis. 2020 Apr 15:annrheumdis-2020-217480. doi: 10.1136/annrheumdis-2020-217480. Epub ahead of print. PMID: 32295786.

17: Mack HG. Hydroxychloroquine use during the COVID-19 pandemic 2020. Aust J Gen Pract. 2020 Apr 14;49. doi: 10.31128/AJGP-COVID-08. Epub ahead of print. PMID: 32294807.

18: Brufsky A. Hyperglycemia, Hydroxychloroquine, and the COVID-19 Epidemic. J Med Virol. 2020 Apr 15. doi: 10.1002/jmv.25887. Epub ahead of print. PMID: 32293710.

19: Zhang TY, Zhong B. Meeting the Potential Emergency Global Drug Supply Challenge of Hydroxychloroquine for COVID-19. Med Drug Discov. 2020 Apr 9:100036. doi: 10.1016/j.medidd.2020.100036. Epub ahead of print. PMID: 32292908; PMCID: PMC7144509.

20: Picot S, Marty A, Bienvenu AL, Blumberg LH, Dupouy-Camet J, Carnevale P, Kano S, Jones MK, Daniel-Ribeiro CT, Mas-Coma S. Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19. One Health. 2020 Apr 4:100131. doi: 10.1016/j.onehlt.2020.100131. Epub ahead of print. PMID: 32292817; PMCID: PMC7128742.